Nicoletta Ciccarelli

Prof. Nicoletta Ciccarelli

Department of Theoretical and Applied Sciences, Università degli Studi eCampus, Novedrate, Italy
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
SGS. Di Giambenedetto
S. Di Giambenedetto
IFI. Fanti
I. Fanti
EBE. Baldonero
E. Baldonero
MSM.C. Silveri
M.C. Silveri
Background: Despite the availability of potent antiretroviral regimens (combination antiretroviral therapy [cART]), HIV-associated neurocognitive disorders (HAND) are increasingly recognized. Our aim was to investigate the prevalence and treatment-related correlates of HAND, exploring the potential neurotoxicity of antiretrovirals on cognitive functions. Methods: We performed a cross-sectional single cohort study by consecutively enrolling asymptomatic HIV+ subjects during routine outpatient visits. Each patient was submitted to a comprehensive neuropsychological battery and was considered cognitively impaired on the basis of results obtained in matched healthy HIV-negative subjects. CNS penetration effectiveness (CPE) rank was calculated for cART regimens according to 2010 CHARTER criteria. Factors associated with cognitive impairment were investigated by linear or logistic regression analysis. Results: A total of 146 patients were enrolled. Of these, 129 (88.4%) were on cART and 59.6% of them were on current regimen from ≥1 year. Sixty-nine patients (47%) were classified as cognitively impaired (35.6% asymptomatic and 11.6% mild neurocognitive impairment). In the multivariate analysis, efavirenz use (odds ratio [OR] = 4.00; p = 0.008) and non-Italian nationality (OR = 3.46; p = 0.035) were associated with increased risk of cognitive impairment, whereas higher education was associated with a lower risk (OR = 0.85; p = 0.002). Furthermore, efavirenz use and age ≥65 years independently predicted worse performance on the double barrage and the Stroop test (time). No association between CPE rank and cognitive impairment was observed. Conclusions: A high prevalence of HAND was observed in apparently asymptomatic HIV+ individuals. HAND was associated with efavirenz use, suggesting the potential neurotoxicity of this drug. Routine neuropsychological examinations could help clinicians make correct diagnoses and manage mild, but clinically relevant, forms of HAND.

21 September 2012 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
MTM Tana
M Tana
SFS Farina
S Farina
EBE Baldonero
E Baldonero
SGS Di Giambenedetto
S Di Giambenedetto

1 October 2009 in Neuropsychologia
Verified
Journal Article
Closed access
MSMaria Caterina Silveri
Maria Caterina Silveri
NCNicoletta Ciccarelli
Nicoletta Ciccarelli

1 July 2012 in Neuropsychologia
Verified
Journal Article
Closed access
MSMaria Caterina Silveri
Maria Caterina Silveri
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
EBEleonora Baldonero
Eleonora Baldonero
CPCarla Piano
Carla Piano
MZMassimiliano Zinno
Massimiliano Zinno
ADAntonio Daniele
Antonio Daniele


1 February 2013 in Antiviral Therapy
Verified
Journal Article
Closed access
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
MCManuela Colafigli
Manuela Colafigli
ETEnrico Maria Trecarichi
Enrico Maria Trecarichi
MSMaria Caterina Silveri
Maria Caterina Silveri
SGSimona Di Giambenedetto
Simona Di Giambenedetto
Background: The objective of our study was to compare two different central nervous system penetration- effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients. Methods: We performed a cross-sectional single cohort study, consecutively enrolled during routine outpatient visits. HIV-infected subjects on antiretroviral therapy with plasma HIV RNA<50 copies/ml were included. A neuropsy-chological battery was administered. Each patient was classified as cognitively impaired on the basis of results obtained in age-, gender-, education- and nationality-matched healthy HIV-negative subjects. Self-reported adherence to antiviral therapy was measured on a 0–100 visual analogue scale. CPE rank was calculated for each antiretroviral regimen based on rules proposed by the CHARTER group in the 2008 original version (orCPE rank) and the 2010 revised version (revCPE rank). Neuroeffectiveness categories were analysed based on cutoffs of ≥1.5 (orCPE rank) or ≥6 (revCPE rank). Results: A total of 101 patients were enrolled (66% male, median age 47 years, median education 13 years); mean adherence was 81%. orCPE rank ≥1.5 and revCPE rank ≥6 were observed in 85.0% and 78.2% of patients, respectively ( P=0.31). Asymptomatic neurocognitive impairment (ANI) was diagnosed in 50 (49.5%) subjects. In a multivariable model, after adjusting for nationality, adherence and nadir CD4 + T-cell count, orCPE rank did not show an association with cognitive performance ( P=0.704). By contrast, patients with revCPE rank ≥6 (OR 0.32, 95% CI 0.11, 0.95; P=0.039) and adherence ≥80% (OR 0.39, 95% CI 0.15, 0.99; P=0.047) showed a decreased risk of cognitive impairment. Conclusions: A high prevalence of ANI was observed in virologically suppressed HIV-infected individuals. The revCPE rank showed improved association with neurocognitive dysfunction over the orCPE rank. Moreover, a relationship between cognitive impairment and adherence to antiretroviral therapy was found.